Efficacy and safety of thalidomide in the treatment of multiple myeloma.
Warzocha
Krzysztof
K
Institute of Hematology and Transfusion Medicine, 14 Indira Gandhi St., 02-776 Warsaw, Poland.
Kraj
Maria
M
Pogłód
Ryszard
R
Szpila
Tomasz
T
Mendek-Czajkowska
Ewa
E
Chełstowska
Monika
M
Tronina
Renata Hagedorna
RH
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D012008:Recurrence; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D013792:Thalidomide